| 1 |
Christopher Norbert Johnson |
Astex Therapeutics Limited |
9 |
| 2 |
Mark Stuart Chambers |
Merck |
3 |
| 2 |
David Tilbrook |
Hexcel Composites Limited |
3 |
| 2 |
Robin M. Bannister |
Infirst Healthcare Limited |
3 |
| #5 |
Silke Ruediger |
Illumina Cambridge Limited |
2 |
| #5 |
John Frederick Atherall |
Xention Limited |
2 |
| #5 |
Christopher A. Luckhurst |
Chdi Foundation |
2 |
| #8 |
Geoffrey Paul Smith |
Illumina Cambridge Limited |
1 |
| #8 |
Edward Palgrave-Moore |
Snell Holdings |
1 |
| #8 |
Reuben Wu |
Johnsondiversey |
1 |
| #8 |
Christoph Hendrik Beckmann |
Biotica Technology Limited |
1 |
| #8 |
Tobias William Barr Ost |
— |
1 |
| #8 |
Clive L. Cornell |
AbbVie |
1 |
| #8 |
Philip Spencer Fallon |
Medivir Ab |
1 |
| #8 |
Andrew Jeffries |
Nortel Networks Limited |
1 |
| #8 |
Karine Fabienne Malagu |
Usher Iii Initiative |
1 |
| #8 |
Peter Massam |
Plextek Limited |
1 |
| #8 |
Helen Bignell |
Illumina Cambridge Limited |
1 |
| #8 |
Jackie Macritchie |
Bayer Pharma |
1 |
| #8 |
Hervé Van De Poël |
Chiesi Farmaceutici S.P.A. |
1 |